Search Bar & Filters
Found 89 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of multiple therapies in participants with early-stage non-small cell lung cancer NSCLC at stages IB through III, including selected IIIB tumors that are resectable and untreated, and meet specific biomarker criteria. This Phase II trial focuses on different treatment approaches based on genetic and molecular features of the tumors. The study aims to assess how well these therapies work before and after surgery to improve outcomes for patients with NSCLC. Participants receive up to 8 weeks of neoadjuvant therapy with one of several study drugs, including alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, atezolizumab combined with stereotactic body radiation therapy SBRT, or divarasib, depending on their biomarker status. After this initial treatment period, participants undergo surgical removal of the tumor following standard care. Those whose tumors show a pathological response or no disease progression then receive adjuvant therapy, which typically includes 4 cycles of chemotherapy followed by up to 2 years of continued therapy with the initial study drug or other specified treatments. Throughout the trial, participants are monitored with imaging scans such as CT, PET, and brain MRI, along with laboratory tests to assess tumor response and safety. Researchers measure outcomes including major pathologic response, complete pathological response, adverse events, and survival rates over up to nine years. The study also evaluates detailed biomarkers like circulating tumor DNA and drug levels in plasma. Participant involvement includes neoadjuvant treatment, surgery, adjuvant therapy, and long-term follow-up visits to track disease-free and overall survival as well as treatment effects.
Actively Recruiting
Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.
Actively Recruiting
Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.
Actively Recruiting
Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are conducting a global phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of fixed doses of SEP-363856 compared to placebo in adults aged 18 years and older with generalized anxiety disorder GAD. This randomized, double-blind, parallel-group, placebo-controlled study aims to assess how well SEP-363856 works in reducing anxiety symptoms over an 8-week period. Participants are assigned to one of three groups one group receives 50 mg of SEP-363856 daily for 56 days another group starts with 50 mg daily for the first 3 days then increases to 75 mg daily through day 56 the third group receives a placebo tablet daily for 56 days. All treatments are taken orally once a day. This structure allows comparison of two fixed doses of SEP-363856 against placebo during the treatment period. During the study, participants will be regularly assessed for changes in anxiety symptoms using the Hamilton Anxiety Rating Scale and Clinical Global Impression-Severity Score at the beginning and end of the 8 weeks. Researchers will monitor safety, tolerability, and response rates. Participants are expected to attend scheduled visits for evaluations, laboratory tests, and adherence checks throughout the 8-week treatment. The total study duration includes screening and treatment phases, concluding after the final assessments at week 8.
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.
1-10 of 89
1